Skip to main content
. 2014 Dec 4;4:7310. doi: 10.1038/srep07310

Figure 5. Rigosertib could modify multiple signaling pathways in MDS and MDS cell lines.

Figure 5

(A) Rigosertib did not affect the expression and phosphorylation levels of signaling transducers, including Akt, p38, SAPK/JNK, STAT3, β-catenin, GSK3α/β and P53, in normal CD34+ cells because it did not activate these proteins; (B) In patients with low-grade MDS, rigosertib administration could somewhat reduce the phosphorylation of Akt, β-catenin and GSK3α/β; (C) In patients with high-grade MDS, rigosertib markedly reduced the phosphorylation of Akt, β-catenin and GSK3α/β, while the phosphorylation of SAPK/JNK and P53 was enhanced; In the SKM1 (D) and MDS-L (E) cell lines, the same results could be observed as in patients with high-grade MDS. (F) Western blot was performed to validate the results acquired from FCM in the MDS-L and SKM1 cell lines. Representative graphic from three experiments was shown. For each patient or cell line, experiments were carried out three times. Error bars throughout represent the SEM. *, P<0.05; **, P<0.01; ***, P<0.001 (two-tailed, student T test).